{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:56:12Z","timestamp":1793850972360,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Backround<\/jats:title>\n                    <jats:p>Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD) has been associated with increased cardiovascular risk. The aim of this Randomized Double-blind clinical Trial was to evaluate the effects of coenzyme-Q10 supplementation in patients with MASLD in terms of endothelial, vascular and myocardial function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sixty patients with MASLD were randomized to receive daily 240\u00a0mg of coenzyme-Q10 or placebo. At baseline and at 6-months, the a)Perfused boundary region of sublingual vessels using the Sideview Darkfield imaging technique, b)pulse-wave-velocity, c)flow-mediated dilation of the brachial artery, d)left ventricular global longitudinal strain, e)coronary flow reserve of the left anterior descending coronary artery and f)controlled attenuation parameter for the quantification of liver steatosis were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six months post-treatment, patients under coenzyme-Q10 showed reduced Perfused boundary region (2.18\u2009\u00b1\u20090.23vs.2.29\u2009\u00b1\u20090.18\u00a0\u03bcm), pulse-wave-velocity (9.5\u2009\u00b1\u20092vs.10.2\u2009\u00b1\u20092.3\u00a0m\/s), controlled attenuation parameter (280.9\u2009\u00b1\u200933.4vs.304.8\u2009\u00b1\u200937.4dB\/m), and increased flow-mediated dilation (6.1\u2009\u00b1\u20093.8vs.4.3\u2009\u00b1\u20092.8%), global longitudinal strain (-19.6\u2009\u00b1\u20091.6vs.-18.8\u2009\u00b1\u20091.9%) and coronary flow reserve (3.1\u2009\u00b1\u20090.4vs.2.8\u2009\u00b1\u20090.4) compared to baseline (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). The placebo group exhibited no improvement during the 6-month follow-up period (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). In patients under coenzyme-Q10, the reduction in controlled attenuation parameter score was positively related to the reduction in Perfused boundary region and pulse wave velocity and reversely related to the increase in coronary flow reserve and flow-mediated dilation (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05 for all relations).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Six-month treatment with high-dose coenzyme-Q10 reduces liver steatosis and improves endothelial, vascular and left ventricle myocardial function in patients with MASLD, demonstrating significant improvements in micro- and macro-vasculature function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>NCT05941910<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-024-02326-8","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T15:01:57Z","timestamp":1720623717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Six-month supplementation with high dose coenzyme Q10 improves liver steatosis, endothelial, vascular and myocardial function in patients with metabolic-dysfunction associated steatotic liver disease: a randomized double-blind, placebo-controlled trial"],"prefix":"10.1186","volume":"23","clinical-trial-number":[{"clinical-trial-number":"nct05941910","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Emmanouil","family":"Vrentzos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignatios","family":"Ikonomidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Pavlidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Katogiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Korakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Kountouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loukia","family":"Pliouta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Michalopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Pelekanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Boumpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaia","family":"Lambadiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"issue":"21","key":"2326_CR1","doi-asserted-by":"publisher","first-page":"7870","DOI":"10.3390\/ijms21217870","volume":"21","author":"Francisco Miguel Gutierrez-Mariscal et","year":"2020","unstructured":"Francisco Miguel Gutierrez-Mariscal et. Al.Coenzyme Q10 supplementation for the Reductionof oxidative stress: clinical implications in the treatment of Chronic diseases. Int J Mol Sci. 2020;21(21):7870.","journal-title":"Int J Mol Sci"},{"issue":"18","key":"2326_CR2","doi-asserted-by":"publisher","first-page":"6695","DOI":"10.3390\/ijms21186695","volume":"21","author":"RA Iain Hargreaves","year":"2020","unstructured":"Iain Hargreaves RA, Heaton. David Mantle, disorders of Human Coenzyme Q10 Metabolism: an overview. Int J Mol Sci. 2020;21(18):6695.","journal-title":"Int J Mol Sci"},{"issue":"25","key":"2326_CR3","doi-asserted-by":"publisher","first-page":"e924","DOI":"10.1161\/CIRCULATIONAHA.105.583815","volume":"113","author":"M Gupta","year":"2006","unstructured":"Gupta M, Singh N, Verma S. South asians and Cardiovascular Risk. Circulation. 2006;113(25):e924\u20139.","journal-title":"Circulation"},{"key":"2326_CR4","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.2174\/1381612824666180406104516","volume":"24","author":"N Sharifi","year":"2018","unstructured":"Sharifi N, Tabrizi R, Moosazadeh M, et al. The effects of Coenzyme Q10 supplementation on lipid profiles among patients with metabolic diseases: a systematic review and Meta-analysis of Randomized controlled trials. Curr Pharm Des. 2018;24:2729\u201342.","journal-title":"Curr Pharm Des"},{"key":"2326_CR5","doi-asserted-by":"publisher","first-page":"s257","DOI":"10.1016\/0098-2997(94)90036-1","volume":"15","author":"V Digiesi","year":"1994","unstructured":"Digiesi V, Cantini F, Oradei A, et al. Coenzyme Q10 in essential hypertension. Mol Asp Med. 1994;15:s257\u201363.","journal-title":"Mol Asp Med"},{"key":"2326_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/biof.5520320115","volume":"32","author":"R Belardinelli","year":"2008","unstructured":"Belardinelli R, Tiano L, Littarru GP. Oxidative stress, endothelial function and coenzyme Q10. BioFactors. 2008;32:129\u201333.","journal-title":"BioFactors"},{"key":"2326_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4187\/respcare.04209","volume":"61","author":"A Sunnetcioglu","year":"2015","unstructured":"Sunnetcioglu A, Alp HH, Ndan BS, Balaharoglu R, et al. Evaluation of oxidative damage and antioxidant mechanisms in COPD, Lung Cancer, and obstructive sleep apnea syndrome. Respir Care. 2015;61:205\u201311.","journal-title":"Respir Care"},{"issue":"1","key":"2326_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/1874609812666191023153724","volume":"14","author":"OJ Onaolapo","year":"2021","unstructured":"Onaolapo OJ, Odeniyi AO, Jonathan SO, et al. An investigation of the anti-parkinsonism potential of co-enzyme Q10 and co-enzyme Q10 \/levodopa-carbidopa combination in mice. Curr Aging Sci Curr Aging Sci. 2021;14(1):62\u201375.","journal-title":"Curr Aging Sci Curr Aging Sci"},{"issue":"8","key":"2326_CR9","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/jamaneurol.2016.1325","volume":"73","author":"T Matsukawa","year":"2016","unstructured":"Matsukawa T, Yasuda T, Ishiura H, Tsuji S. Plasma coenzyme Q10 levels in patients with multiple system atrophy. JAMA Neurol. 2016;73(8):977\u201380.","journal-title":"JAMA Neurol"},{"key":"2326_CR10","first-page":"S412","volume":"50","author":"SK Erickson","year":"2009","unstructured":"Erickson SK. Nonalcoholic fatty liver disease. J LipidRes. 2009;50:S412\u20136.","journal-title":"J LipidRes"},{"key":"2326_CR11","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.metabol.2006.07.021","volume":"55","author":"S-Y Oh","year":"2006","unstructured":"Oh S-Y, Cho Y-K, Kang M-S, et al. The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism. 2006;55:1604\u20139.","journal-title":"Metabolism"},{"key":"2326_CR12","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jhep.2010.09.022","volume":"54","author":"E Novo","year":"2011","unstructured":"Novo E, Busletta C, Di Bonzo LV, et al. Intracellular reactive oxygen species are required for directional migration of resident and bone marrow-derived hepatic pro-fibrogenic cells. J Hepatol. 2011;54:964\u201374.","journal-title":"J Hepatol"},{"key":"2326_CR13","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/j.1478-3231.2011.02604.x","volume":"31","author":"AK Singal","year":"2011","unstructured":"Singal AK, Jampana SC, Weinman S. Antioxidants as therapeutic agents for liver disease. Liver Int. 2011;31:1432\u201348.","journal-title":"Liver Int"},{"key":"2326_CR14","unstructured":"Food US, Administration D. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease, https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease, Accessed 14 Mar 2024."},{"key":"2326_CR15","doi-asserted-by":"crossref","unstructured":"Li Rong J, Zou W, Ran et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne) 2023 Jan 16:131087260.","DOI":"10.3389\/fendo.2022.1087260"},{"issue":"6","key":"2326_CR16","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"E Mary","year":"2023","unstructured":"Mary E, Rinella. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966\u201386.","journal-title":"Hepatology"},{"key":"2326_CR17","doi-asserted-by":"crossref","unstructured":"Kamali L, Adibi A, Ebrahimian S, Jafari F, Sharifi M. Diagnostic performance of ultrasonography in detecting fatty liver disease in comparison with Fibroscan in people suspected of fatty liver. Adv Biomed Res 2019 Nov 27:869.","DOI":"10.4103\/abr.abr_114_19"},{"issue":"9","key":"2326_CR18","doi-asserted-by":"publisher","first-page":"e015716","DOI":"10.1161\/JAHA.119.015716","volume":"9","author":"I Ikonomidis","year":"2020","unstructured":"Ikonomidis I, et al. Effects of Glucagon-Like Peptide-1 receptor agonists, sodium-glucose Cotransporter-2 inhibitors, and their combination on endothelial glycocalyx, arterial function, and myocardial work index in patients with type 2 diabetes Mellitus after 12-Month treatment. J Am Heart Assoc. 2020;9(9):e015716.","journal-title":"J Am Heart Assoc"},{"key":"2326_CR19","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1177\/1741826711398179","volume":"18","author":"J Lekakis","year":"2011","unstructured":"Lekakis J, Abraham P, Balbarini A, et al. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral circulation. Eur J Cardiovasc Prev Rehabil. 2011;18:775\u201389.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2326_CR20","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, ESC Scientific Document Group, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"2326_CR21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cjca.2014.11.002","volume":"31","author":"I Ikonomidis","year":"2015","unstructured":"Ikonomidis I, Makavos G, Papadavid E, et al. Similarities in coronary function and myocardial deformation betweenpsoriasis and coronary artery disease: the role of oxidative stress and inflammation. Can J Cardiol. 2015;31:287\u201395.","journal-title":"Can J Cardiol"},{"key":"2326_CR22","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/ehjci\/jex140","volume":"18","author":"T Sugimoto","year":"2017","unstructured":"Sugimoto T, Dulgheru R, Bernard A, et al. Echocardiographic reference ranges for normal left ventricular 2D strain: results from the EACVI NORRE study. Eur Heart J Cardiovasc Imaging. 2017;18:833\u201340.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"18","key":"2326_CR23","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/heartjnl-2019-316215","volume":"106","author":"P Rachid Abou","year":"2020","unstructured":"Rachid Abou P, van der Bijl JJ, Bax V, Delgado. Global longitudinal strain: clinical use and prognostic implications in contemporary practice. Heart. 2020;106(18):1438\u201344.","journal-title":"Heart"},{"issue":"7","key":"2326_CR24","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/ajh.2008.172","volume":"21","author":"I Ikonomidis","year":"2008","unstructured":"Ikonomidis I, Lekakis J, Papadopoulos C, Triantafyllidi H, Paraskevaidis I, Georgoula G, et al. Incremental value of pulse wave velocity in the determination of coronary microcirculatory dysfunction in never-treated patients with essential hypertension. Am J Hypertens. 2008;21(7):806\u201313.","journal-title":"Am J Hypertens"},{"issue":"5","key":"2326_CR25","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1161\/hc0502.103333","volume":"105","author":"G Arcaro","year":"2002","unstructured":"Arcaro G, Cretti A, Balzano S, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation. 2002;105(5):576\u201382.","journal-title":"Circulation"},{"key":"2326_CR26","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1161\/CIRCIMAGING.113.001193","volume":"7","author":"I Ikonomidis","year":"2014","unstructured":"Ikonomidis I, Tzortzis S, Andreadou I, et al. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging. 2014;7:619\u201328.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"2326_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40292-014-0047-2","volume":"22","author":"M Lorenzo Ghiadoni","year":"2015","unstructured":"Lorenzo Ghiadoni M, Salvetti ML, Muiesan S, Taddei. Evaluation of endothelial function by flow mediated dilation: methodological issues and clinical importance. High Blood Press Cardiovasc Prev. 2015;22(1):17\u201322.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"6","key":"2326_CR28","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/fsn3.3315","volume":"11","author":"A Ardekani","year":"2023","unstructured":"Ardekani A, Tabrizi R, Maleki E, et al. Effects of coenzyme Q10 supplementation on lipid profiles and liver enzymes of nonalcoholic fatty liver disease (NAFLD) patients: a systematic review and meta-analysis of randomized controlled trials. Food Sci Nutr. 2023;11(6):2580\u20138.","journal-title":"Food Sci Nutr"},{"issue":"10","key":"2326_CR29","first-page":"544","volume":"56","author":"A Annalisa Curcio","year":"2020","unstructured":"Annalisa Curcio A, Romano S, Cuozzo, et al. Silymarin in combination with vitamin C, vitamin E, coenzyme Q10 and selenomethionine to improve liver enzymes and blood lipid profile in NAFLD patients. Med (Kaunas). 2020;56(10):544.","journal-title":"Med (Kaunas)"},{"key":"2326_CR30","doi-asserted-by":"crossref","unstructured":"Farnaz Farsi M, Mohammadshahi PA, et al. Functions of Coenzyme Q10 supplementation on liver enzymes, markers of systemic inflammation, and Adipokines in patients affected by nonalcoholic fatty liver disease: a Double-Blind, Placebo-Controlled, Randomized Clinical Trial. J Am Coll Nutr. 2016 May-Jun;35(4):346\u201353.","DOI":"10.1080\/07315724.2015.1021057"},{"issue":"1","key":"2326_CR31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/gerona\/glu098","volume":"70","author":"L Gonz\u00e1lez-Guardia","year":"2015","unstructured":"Gonz\u00e1lez-Guardia L, Yubero-Serrano EM, Gomez-Delgado F, et al. Effects of the Mediterranean Diet supplemented with Coenzyme Q10 on Metabolomic profiles in Elderly men and women. J Gerontol Biol Sci Med Sci. 2015;70(1):78\u201384.","journal-title":"J Gerontol Biol Sci Med Sci"},{"issue":"2","key":"2326_CR32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/ajh.2011.209","volume":"25","author":"JM Young","year":"2012","unstructured":"Young JM, Florkowski CM, Molyneux SL, et al. A Randomized, Double-Blind, placebo-controlled crossover study of Coenzyme Q10 Therapy in Hypertensive patients with the metabolic syndrome. Am J Hypertens. 2012;25(2):261\u201370.","journal-title":"Am J Hypertens"},{"issue":"5","key":"2326_CR33","doi-asserted-by":"publisher","first-page":"810","DOI":"10.2337\/dc08-1736","volume":"32","author":"J Sandra","year":"2009","unstructured":"Sandra J, Hamilton GT, Chew, Gerald F, Watts. Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients. Diabetes Care. 2009;32(5):810\u20132.","journal-title":"Diabetes Care"},{"issue":"3","key":"2326_CR34","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s00125-001-0760-y","volume":"45","author":"GF Watts","year":"2002","unstructured":"Watts GF, Playford DA, Croft KD, Ward NC, Mori TA, Burke V. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in type II diabetes mellitus. Diabetologia. 2002;45(3):420\u20136.","journal-title":"Diabetologia"},{"issue":"1","key":"2326_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.nut.2012.03.016","volume":"29","author":"VN Larijani","year":"2013","unstructured":"Larijani VN, Ahmadi N, Zeb I, et al. Beneficial effects of aged garlic extract and coenzyme Q10 on vascular elasticity and endothelial function: the FAITH randomized clinical trial. Nutrition. 2013;29(1):71\u20135.","journal-title":"Nutrition"},{"issue":"12","key":"2326_CR36","doi-asserted-by":"publisher","first-page":"e0141641","DOI":"10.1371\/journal.pone.0141641","volume":"10","author":"J Urban Alehagen","year":"2015","unstructured":"Urban Alehagen J, Aaseth P, Johansso. Reduced Cardiovascular Mortality 10 years after supplementation with selenium and Coenzyme Q10 for four years: Follow-Up results of a prospective Randomized double-blind placebo-controlled trial in Elderly citizens. PLoS ONE. 2015;10(12):e0141641.","journal-title":"PLoS ONE"},{"issue":"6","key":"2326_CR37","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jchf.2014.06.008","volume":"2","author":"A Svend","year":"2014","unstructured":"Svend A, Mortensen F, Rosenfeldt A, Kumar, et al. Q-SYMBIO study investigators, the effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2(6):641\u20139.","journal-title":"JACC Heart Fail"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02326-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02326-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02326-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T15:02:21Z","timestamp":1720623741000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02326-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2326"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02326-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4117479\/v1","asserted-by":"object"}]},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]},"assertion":[{"value":"17 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"<b>Not applicable<\/b>.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"V.L. has given lectures, attended conferences and participated in\u00a0trials sponsored by Novo Nordisk, Sanofi-Aventis, Novartis,\u00a0Astrazeneca, BoehringerIngelheim, MSD, GSK, Vianex, Elli Lilly,\u00a0ELPEN, Mylan and Aegereon.\u00a0The rest of the authors declare that they have no competing\u00a0interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Institutional Review Board of University General Hospital \u201cAttikon\u201d gave their approval to the study protocol (Approval number: 441\/13-07-2022). All participants provided written consent to participate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}}],"article-number":"245"}}